WAYRILZ Drug Patent Profile

When do Wayrilz patents expire, and what generic alternatives are available?

Wayrilz is a drug marketed by Genzyme Corp and is included in one NDA. There are six patents protecting this drug.

This drug has ninety-four patent family members in thirty-four countries.

The generic ingredient in WAYRILZ is rilzabrutinib. One supplier is listed for this compound. Additional details are available on the rilzabrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Wayrilz

Wayrilz will be eligible for patent challenges on August 29, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 29, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for WAYRILZ

International Patents:	94
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	571
What excipients (inactive ingredients) are in WAYRILZ?	WAYRILZ excipients list
DailyMed Link:	WAYRILZ at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WAYRILZ

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219685

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for WAYRILZ

WAYRILZ is protected by seven US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes			Y	Y
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes			Y	Y
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes			Y	Y
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes				Y

International Patents for WAYRILZ

See the table below for patents covering WAYRILZ around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	120803
Australia	2020405096
Brazil	112022011516
Canada	3162219
China	115515687
Colombia	2022008023

Supplementary Protection Certificates for WAYRILZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3181567	C20260015	Finland
3181567	301380	Netherlands		PRODUCT NAME: RILZABRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/25/1974 20251223
3181567	CR 2026 00022	Denmark		PRODUCT NAME: RILZABRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/25/1974 20261223
3181567	PA2026520	Lithuania		PRODUCT NAME: WAYRILZ - RILZABRUTINIBAS; REGISTRATION NO/DATE: EU/1/25/1974 20251222
3181567	LUC50052	Luxembourg		PRODUCT NAME: RILZABRUTINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/25/1974 20251223

Last updated: April 25, 2026

WAYRILZ: Market Dynamics and Financial Trajectory

What is WAYRILZ and where does it sit in the market?

WAYRILZ is not sufficiently identified in the provided context to anchor a factual market-sizing or financial-trajectory analysis. No drug identity attributes (active ingredient, dosage form, label indication, or authorization geography) are available, and “WAYRILZ” could refer to multiple naming conventions across jurisdictions, press releases, or pipeline/brand placeholders. With no verified product definition, any claims about pricing, sales, payer uptake, or revenue trajectory would not be grounded in verifiable facts.

How do market dynamics typically shape uptake for drugs like WAYRILZ?

Without the actual therapeutic area, mechanism, and approved indications for WAYRILZ, market dynamics cannot be mapped to defensible drivers (e.g., biosimilar intensity, payer restrictiveness, formulary access timing, site-of-care constraints, or competitive class structure). A market-dynamics framework depends on:

• Therapeutic category (oncology vs immunology vs rare disease vs infectious disease changes demand formation and contracting models)
• Indication breadth (narrow label vs multi-line use changes target population and sequencing)
• Administration model (oral vs infusion vs injection shifts access barriers, adherence, and channel economics)
• Comparator landscape (single SOC vs multiple competitors affects price erosion and share retention)

No such attributes are available for WAYRILZ in the prompt, so the analysis cannot be completed without generating unsupported conclusions.

What is the financial trajectory for WAYRILZ?

A financial trajectory requires at least one of the following factual anchors:

• historic sales (monthly, quarterly, or annual) by geography
• manufacturing/distribution milestones that indicate launch ramp
• public company segment reporting that includes WAYRILZ revenue
• payer coverage and reimbursement signal tied to realized demand

No revenue data, launch date, or corporate disclosure is provided, so a sales ramp or profit path cannot be stated as fact.

Market and financial model that would normally be used (but cannot be populated)

A typical drug commercialization model for a branded pharmaceutical tracks:

• Launch kinetics: prescription or patient starts, by channel (hospital vs retail)
• Pricing path: WAC/list price vs net price after rebates and discounts
• Market access milestones: formulary position, prior authorization requirements, step edits
• Competitive pressure: entry timing of next-generation agents or generics/biosimilars
• Retention: persistence and switching behavior under long-term therapy

Populating this model for WAYRILZ requires validated product identity and disclosure data that are not present.

---

Key Takeaways

1. WAYRILZ cannot be tied to an unambiguous drug identity from the provided information, so market dynamics and financial trajectory for the product cannot be stated as factual analysis.
2. Market drivers and the financial path depend on therapeutic class, indications, administration, and competition; none are available for WAYRILZ in the prompt.
3. Sales and revenue trajectory require disclosed or verifiable sales figures and launch/access milestones; none are provided.

FAQs

1. Is WAYRILZ a brand or a pipeline codename?
   The prompt does not specify whether WAYRILZ is an approved marketed product, a brand under development, or a non-final placeholder.

2. What is WAYRILZ’s active ingredient and indication?
   The prompt provides no active ingredient or indication.

3. When was WAYRILZ launched and in which countries?
   No launch date or geography is provided.

4. What is the pricing and net-revenue pathway for WAYRILZ?
   No pricing, rebate, or net sales disclosure is provided.

5. Who are WAYRILZ’s competitors in the therapeutic space?
   The prompt does not provide therapeutic category, mechanism, or indication, so competitors cannot be identified.

---

References

[1] No cited sources are available because WAYRILZ’s validated product identity, indications, and financial disclosure are not provided in the prompt.